ID   PTGIS_HUMAN             Reviewed;         500 AA.
AC   Q16647; Q3MII8; Q9HAX2; Q9HAX3; Q9HAX4;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   28-JUN-2023, entry version 202.
DE   RecName: Full=Prostacyclin synthase;
DE            EC=5.3.99.4 {ECO:0000269|PubMed:15115769, ECO:0000269|PubMed:18032380, ECO:0000269|PubMed:25623425};
DE   AltName: Full=Hydroperoxy icosatetraenoate dehydratase {ECO:0000305};
DE            EC=4.2.1.152 {ECO:0000269|PubMed:17459323};
DE   AltName: Full=Prostaglandin I2 synthase;
GN   Name=PTGIS; Synonyms=CYP8, CYP8A1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Aorta;
RX   PubMed=8185632; DOI=10.1006/bbrc.1994.1652;
RA   Miyata A., Hara S., Yokoyama C., Inoue H., Ullrich V., Tanabe T.;
RT   "Molecular cloning and expression of human prostacyclin synthase.";
RL   Biochem. Biophys. Res. Commun. 200:1728-1734(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS LEU-38; ARG-118 AND SER-379.
RX   PubMed=11281454; DOI=10.1007/s004390000444;
RA   Chevalier D., Cauffiez C., Bernard C., Lo-Guidice J.-M., Allorge D.,
RA   Fazio F., Ferrari N., Libersa C., Lhermitte M., D'Halluin J.C., Broly F.;
RT   "Characterization of new mutations in the coding sequence and 5'-
RT   untranslated region of the human prostacyclin synthase gene (CYP8A1).";
RL   Hum. Genet. 108:148-155(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INVOLVEMENT IN EHT.
RX   PubMed=12372404; DOI=10.1016/s0006-291x(02)02341-0;
RA   Nakayama T., Soma M., Watanabe Y., Hasimu B., Sato M., Aoi N., Kosuge K.,
RA   Kanmatsuse K., Kokubun S., Marrow J.D., Oates J.A.;
RT   "Splicing mutation of the prostacyclin synthase gene in a family associated
RT   with hypertension.";
RL   Biochem. Biophys. Res. Commun. 297:1135-1139(2002).
RN   [6]
RP   CATALYTIC ACTIVITY, FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   MUTAGENESIS OF CYS-441.
RX   PubMed=15115769; DOI=10.1093/jb/mvh059;
RA   Wada M., Yokoyama C., Hatae T., Shimonishi M., Nakamura M., Imai Y.,
RA   Ullrich V., Tanabe T.;
RT   "Purification and characterization of recombinant human prostacyclin
RT   synthase.";
RL   J. Biochem. 135:455-463(2004).
RN   [7]
RP   CATALYTIC ACTIVITY, FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=17459323; DOI=10.1016/j.abb.2007.03.012;
RA   Yeh H.C., Tsai A.L., Wang L.H.;
RT   "Reaction mechanisms of 15-hydroperoxyeicosatetraenoic acid catalyzed by
RT   human prostacyclin and thromboxane synthases.";
RL   Arch. Biochem. Biophys. 461:159-168(2007).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, VARIANT
RP   THR-447, AND CHARACTERIZATION OF VARIANT THR-447.
RX   PubMed=25623425; DOI=10.1016/j.abb.2015.01.012;
RA   Cho S.A., Rohn-Glowacki K.J., Jarrar Y.B., Yi M., Kim W.Y., Shin J.G.,
RA   Lee S.J.;
RT   "Analysis of genetic polymorphism and biochemical characterization of a
RT   functionally decreased variant in prostacyclin synthase gene (CYP8A1) in
RT   humans.";
RL   Arch. Biochem. Biophys. 569C:10-18(2015).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 23-500 IN COMPLEX WITH HEME, AND
RP   COFACTOR.
RX   PubMed=17020766; DOI=10.1016/j.jmb.2006.09.039;
RA   Chiang C.W., Yeh H.C., Wang L.H., Chan N.L.;
RT   "Crystal structure of the human prostacyclin synthase.";
RL   J. Mol. Biol. 364:266-274(2006).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.62 ANGSTROMS) OF 18-500 IN COMPLEX WITH HEME AND
RP   INHIBITOR MINOXIDIL, FUNCTION, CATALYTIC ACTIVITY, COFACTOR, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=18032380; DOI=10.1074/jbc.m707470200;
RA   Li Y.C., Chiang C.W., Yeh H.C., Hsu P.Y., Whitby F.G., Wang L.H.,
RA   Chan N.L.;
RT   "Structures of prostacyclin synthase and its complexes with substrate
RT   analog and inhibitor reveal a ligand-specific heme conformation change.";
RL   J. Biol. Chem. 283:2917-2926(2008).
CC   -!- FUNCTION: Catalyzes the biosynthesis and metabolism of eicosanoids.
CC       Catalyzes the isomerization of prostaglandin H2 to prostacyclin (=
CC       prostaglandin I2), a potent mediator of vasodilation and inhibitor of
CC       platelet aggregation (PubMed:18032380, PubMed:25623425,
CC       PubMed:12372404, PubMed:15115769). Additionally, displays dehydratase
CC       activity, toward hydroperoxyeicosatetraenoates (HPETEs), especially
CC       toward (15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoate (15(S)-
CC       HPETE) (PubMed:17459323). {ECO:0000269|PubMed:12372404,
CC       ECO:0000269|PubMed:15115769, ECO:0000269|PubMed:17459323,
CC       ECO:0000269|PubMed:18032380, ECO:0000269|PubMed:25623425}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=prostaglandin H2 = prostaglandin I2; Xref=Rhea:RHEA:23580,
CC         ChEBI:CHEBI:57403, ChEBI:CHEBI:57405; EC=5.3.99.4;
CC         Evidence={ECO:0000269|PubMed:15115769, ECO:0000269|PubMed:18032380,
CC         ECO:0000269|PubMed:25623425};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:23581;
CC         Evidence={ECO:0000305|PubMed:15115769, ECO:0000305|PubMed:18032380,
CC         ECO:0000305|PubMed:25623425};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a hydroperoxyeicosatetraenoate = an oxoeicosatetraenoate +
CC         H2O; Xref=Rhea:RHEA:55556, ChEBI:CHEBI:15377, ChEBI:CHEBI:59720,
CC         ChEBI:CHEBI:131859; EC=4.2.1.152;
CC         Evidence={ECO:0000269|PubMed:17459323};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:55557;
CC         Evidence={ECO:0000269|PubMed:17459323};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoate = 15-oxo-
CC         (5Z,8Z,11Z,13E)-eicosatetraenoate + H2O; Xref=Rhea:RHEA:48636,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:57410, ChEBI:CHEBI:57446;
CC         Evidence={ECO:0000269|PubMed:17459323};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48637;
CC         Evidence={ECO:0000305|PubMed:17459323};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoate + AH2 =
CC         (5Z,8Z,11Z,13E,15S)-hydroxyeicosatetraenoate + A + H2O;
CC         Xref=Rhea:RHEA:48856, ChEBI:CHEBI:13193, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:17499, ChEBI:CHEBI:57409, ChEBI:CHEBI:57446;
CC         Evidence={ECO:0000269|PubMed:17459323};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48857;
CC         Evidence={ECO:0000305|PubMed:17459323};
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413;
CC         Evidence={ECO:0000269|PubMed:17020766, ECO:0000269|PubMed:18032380};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=9.55 uM for 6-keto-PGF1alpha {ECO:0000269|PubMed:25623425};
CC         KM=30 uM for prostaglandin H2 {ECO:0000269|PubMed:15115769};
CC         KM=60 uM for (15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoate
CC         {ECO:0000269|PubMed:17459323};
CC         KM=13 uM for prostaglandin H2 (at 23 degrees Celsius)
CC         {ECO:0000269|PubMed:18032380};
CC         Vmax=534 mmol/min/pg enzyme with prostaglandin H2 as substrate
CC         {ECO:0000269|PubMed:25623425};
CC         Vmax=15 umol/min/mg enzyme with prostaglandin H2 as substrate
CC         {ECO:0000269|PubMed:15115769};
CC         Vmax=980 mol/min/mol enzyme with prostaglandin H2 as substrate
CC         {ECO:0000269|PubMed:18032380};
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000250|UniProtKB:Q29626}; Single-pass membrane protein
CC       {ECO:0000255}.
CC   -!- TISSUE SPECIFICITY: Widely expressed; particularly abundant in ovary,
CC       heart, skeletal muscle, lung and prostate.
CC       {ECO:0000269|PubMed:8185632}.
CC   -!- DISEASE: Essential hypertension (EHT) [MIM:145500]: A condition in
CC       which blood pressure is consistently higher than normal with no
CC       identifiable cause. {ECO:0000269|PubMed:12372404}. Note=The disease may
CC       be caused by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=PharmVar Pharmacogen Variation Consortium;
CC       Note=CYP8A1 alleles;
CC       URL="https://www.pharmvar.org/gene/PTGIS";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/44219/PTGIS";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D38145; BAA07343.1; -; mRNA.
DR   EMBL; AF297048; AAG31781.1; -; mRNA.
DR   EMBL; AF297049; AAG31782.1; -; mRNA.
DR   EMBL; AF297050; AAG31783.1; -; mRNA.
DR   EMBL; AF297051; AAG31784.1; -; mRNA.
DR   EMBL; AF297052; AAG31785.1; -; mRNA.
DR   EMBL; AL118525; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC101809; AAI01810.1; -; mRNA.
DR   EMBL; BC101811; AAI01812.1; -; mRNA.
DR   CCDS; CCDS13419.1; -.
DR   PIR; JC2231; JC2231.
DR   RefSeq; NP_000952.1; NM_000961.3.
DR   PDB; 2IAG; X-ray; 2.15 A; A/B=23-500.
DR   PDB; 3B6H; X-ray; 1.62 A; A/B=18-500.
DR   PDBsum; 2IAG; -.
DR   PDBsum; 3B6H; -.
DR   AlphaFoldDB; Q16647; -.
DR   SMR; Q16647; -.
DR   BioGRID; 111712; 5.
DR   IntAct; Q16647; 1.
DR   STRING; 9606.ENSP00000244043; -.
DR   BindingDB; Q16647; -.
DR   ChEMBL; CHEMBL4428; -.
DR   DrugBank; DB08675; (5Z)-7-{(1R,4S,5R,6R)-6-[(1E)-1-Octen-1-yl]-2,3-diazabicyclo[2.2.1]hept-2-en-5-yl}-5-heptenoic acid.
DR   DrugBank; DB01240; Epoprostenol.
DR   DrugBank; DB00812; Phenylbutazone.
DR   DrugCentral; Q16647; -.
DR   GuidetoPHARMACOLOGY; 1356; -.
DR   SwissLipids; SLP:000001097; -.
DR   CarbonylDB; Q16647; -.
DR   iPTMnet; Q16647; -.
DR   PhosphoSitePlus; Q16647; -.
DR   BioMuta; PTGIS; -.
DR   DMDM; 2493373; -.
DR   EPD; Q16647; -.
DR   jPOST; Q16647; -.
DR   MassIVE; Q16647; -.
DR   MaxQB; Q16647; -.
DR   PaxDb; Q16647; -.
DR   PeptideAtlas; Q16647; -.
DR   ProteomicsDB; 60999; -.
DR   Antibodypedia; 2399; 277 antibodies from 33 providers.
DR   DNASU; 5740; -.
DR   Ensembl; ENST00000244043.5; ENSP00000244043.3; ENSG00000124212.6.
DR   GeneID; 5740; -.
DR   KEGG; hsa:5740; -.
DR   MANE-Select; ENST00000244043.5; ENSP00000244043.3; NM_000961.4; NP_000952.1.
DR   UCSC; uc002xut.4; human.
DR   AGR; HGNC:9603; -.
DR   CTD; 5740; -.
DR   DisGeNET; 5740; -.
DR   GeneCards; PTGIS; -.
DR   HGNC; HGNC:9603; PTGIS.
DR   HPA; ENSG00000124212; Tissue enhanced (fallopian tube, urinary bladder).
DR   MalaCards; PTGIS; -.
DR   MIM; 145500; phenotype.
DR   MIM; 601699; gene.
DR   neXtProt; NX_Q16647; -.
DR   OpenTargets; ENSG00000124212; -.
DR   Orphanet; 243761; NON RARE IN EUROPE: Essential hypertension.
DR   PharmGKB; PA292; -.
DR   VEuPathDB; HostDB:ENSG00000124212; -.
DR   eggNOG; KOG0684; Eukaryota.
DR   GeneTree; ENSGT00940000153709; -.
DR   HOGENOM; CLU_018012_1_3_1; -.
DR   InParanoid; Q16647; -.
DR   OMA; KFITRMK; -.
DR   OrthoDB; 1537669at2759; -.
DR   PhylomeDB; Q16647; -.
DR   TreeFam; TF105090; -.
DR   BioCyc; MetaCyc:HS04738-MON; -.
DR   BRENDA; 5.3.99.4; 2681.
DR   PathwayCommons; Q16647; -.
DR   Reactome; R-HSA-193368; Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol.
DR   Reactome; R-HSA-193775; Synthesis of bile acids and bile salts via 24-hydroxycholesterol.
DR   Reactome; R-HSA-193807; Synthesis of bile acids and bile salts via 27-hydroxycholesterol.
DR   Reactome; R-HSA-197264; Nicotinamide salvaging.
DR   Reactome; R-HSA-211979; Eicosanoids.
DR   Reactome; R-HSA-211994; Sterols are 12-hydroxylated by CYP8B1.
DR   Reactome; R-HSA-2162123; Synthesis of Prostaglandins (PG) and Thromboxanes (TX).
DR   SABIO-RK; Q16647; -.
DR   SignaLink; Q16647; -.
DR   BioGRID-ORCS; 5740; 14 hits in 1164 CRISPR screens.
DR   ChiTaRS; PTGIS; human.
DR   EvolutionaryTrace; Q16647; -.
DR   GeneWiki; Prostacyclin_synthase; -.
DR   GenomeRNAi; 5740; -.
DR   Pharos; Q16647; Tchem.
DR   PRO; PR:Q16647; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; Q16647; protein.
DR   Bgee; ENSG00000124212; Expressed in parietal pleura and 167 other tissues.
DR   Genevisible; Q16647; HS.
DR   GO; GO:0005901; C:caveola; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; ISS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0020037; F:heme binding; IDA:UniProtKB.
DR   GO; GO:0106256; F:hydroperoxy icosatetraenoate dehydratase activity; IEA:UniProtKB-EC.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0004497; F:monooxygenase activity; IEA:InterPro.
DR   GO; GO:0016705; F:oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen; IEA:InterPro.
DR   GO; GO:0008116; F:prostaglandin-I synthase activity; IDA:UniProtKB.
DR   GO; GO:0097190; P:apoptotic signaling pathway; IDA:UniProtKB.
DR   GO; GO:0071456; P:cellular response to hypoxia; IDA:UniProtKB.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEP:UniProtKB.
DR   GO; GO:0071354; P:cellular response to interleukin-6; IEP:UniProtKB.
DR   GO; GO:0019371; P:cyclooxygenase pathway; TAS:Reactome.
DR   GO; GO:0006690; P:icosanoid metabolic process; IDA:UniProtKB.
DR   GO; GO:0034356; P:NAD biosynthesis via nicotinamide riboside salvage pathway; TAS:Reactome.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IDA:UniProtKB.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0045019; P:negative regulation of nitric oxide biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IDA:UniProtKB.
DR   GO; GO:0035360; P:positive regulation of peroxisome proliferator activated receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0001516; P:prostaglandin biosynthetic process; IDA:UniProtKB.
DR   CDD; cd20634; PGIS_CYP8A1; 1.
DR   DisProt; DP02578; -.
DR   Gene3D; 1.10.630.10; Cytochrome P450; 1.
DR   InterPro; IPR001128; Cyt_P450.
DR   InterPro; IPR024204; Cyt_P450_CYP7A1-type.
DR   InterPro; IPR002403; Cyt_P450_E_grp-IV.
DR   InterPro; IPR036396; Cyt_P450_sf.
DR   InterPro; IPR027286; PTGIS.
DR   PANTHER; PTHR24306; -; 1.
DR   PANTHER; PTHR24306:SF4; PROSTACYCLIN SYNTHASE; 1.
DR   Pfam; PF00067; p450; 1.
DR   PIRSF; PIRSF000047; Cytochrome_CYPVIIA1; 1.
DR   PIRSF; PIRSF500628; PTGIS; 1.
DR   PRINTS; PR00465; EP450IV.
DR   SUPFAM; SSF48264; Cytochrome P450; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Endoplasmic reticulum; Fatty acid biosynthesis;
KW   Fatty acid metabolism; Heme; Iron; Isomerase; Lipid biosynthesis;
KW   Lipid metabolism; Lyase; Membrane; Metal-binding;
KW   Prostaglandin biosynthesis; Prostaglandin metabolism; Reference proteome;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..500
FT                   /note="Prostacyclin synthase"
FT                   /id="PRO_0000051910"
FT   TRANSMEM        1..20
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   BINDING         106
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:F1RE08"
FT   BINDING         112
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:F1RE08"
FT   BINDING         287
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:F1RE08"
FT   BINDING         358..359
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:F1RE08"
FT   BINDING         382
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:F1RE08"
FT   BINDING         441
FT                   /ligand="heme"
FT                   /ligand_id="ChEBI:CHEBI:30413"
FT                   /ligand_part="Fe"
FT                   /ligand_part_id="ChEBI:CHEBI:18248"
FT                   /note="axial binding residue"
FT                   /evidence="ECO:0000269|PubMed:17020766,
FT                   ECO:0000269|PubMed:18032380, ECO:0007744|PDB:2IAG,
FT                   ECO:0007744|PDB:3B6H"
FT   VARIANT         38
FT                   /note="P -> L (in allele CYP8A1*2; dbSNP:rs1173082660)"
FT                   /evidence="ECO:0000269|PubMed:11281454"
FT                   /id="VAR_010915"
FT   VARIANT         118
FT                   /note="S -> R (in allele CYP8A1*3; dbSNP:rs5622)"
FT                   /evidence="ECO:0000269|PubMed:11281454"
FT                   /id="VAR_010916"
FT   VARIANT         154
FT                   /note="E -> A (in dbSNP:rs5623)"
FT                   /id="VAR_014634"
FT   VARIANT         171
FT                   /note="F -> L (in dbSNP:rs5624)"
FT                   /id="VAR_014635"
FT   VARIANT         236
FT                   /note="R -> C (in dbSNP:rs5626)"
FT                   /id="VAR_014636"
FT   VARIANT         379
FT                   /note="R -> S (in allele CYP8A1*4; dbSNP:rs56195291)"
FT                   /evidence="ECO:0000269|PubMed:11281454"
FT                   /id="VAR_010917"
FT   VARIANT         447
FT                   /note="A -> T (in allele CYP8A1*5; results in a
FT                   significantly decreased enzyme activity;
FT                   dbSNP:rs146531327)"
FT                   /evidence="ECO:0000269|PubMed:25623425"
FT                   /id="VAR_073186"
FT   VARIANT         500
FT                   /note="P -> S (in dbSNP:rs5584)"
FT                   /id="VAR_014637"
FT   MUTAGEN         441
FT                   /note="C->H: Abolishes prostaglandin-I synthase activity."
FT                   /evidence="ECO:0000269|PubMed:15115769"
FT   TURN            38..40
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   HELIX           43..48
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   HELIX           50..61
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   STRAND          63..69
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   STRAND          72..77
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   HELIX           80..82
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   HELIX           83..87
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   TURN            91..93
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   STRAND          94..96
FT                   /evidence="ECO:0007829|PDB:2IAG"
FT   HELIX           98..106
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   HELIX           117..125
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   HELIX           130..155
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   STRAND          160..163
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   HELIX           164..181
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   HELIX           190..219
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   HELIX           224..240
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   HELIX           243..246
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   HELIX           254..265
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   HELIX           270..285
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   HELIX           288..300
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   HELIX           303..318
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   HELIX           333..336
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   HELIX           339..352
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   STRAND          357..361
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   STRAND          365..368
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   STRAND          374..377
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   STRAND          382..385
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   HELIX           388..392
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   TURN            395..397
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   STRAND          398..400
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   TURN            406..409
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   STRAND          414..416
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   HELIX           444..460
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   STRAND          462..468
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   HELIX           478..480
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   STRAND          482..485
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   STRAND          488..490
FT                   /evidence="ECO:0007829|PDB:3B6H"
FT   STRAND          493..498
FT                   /evidence="ECO:0007829|PDB:3B6H"
SQ   SEQUENCE   500 AA;  57104 MW;  39595442BFC0B625 CRC64;
     MAWAALLGLL AALLLLLLLS RRRTRRPGEP PLDLGSIPWL GYALDFGKDA ASFLTRMKEK
     HGDIFTILVG GRYVTVLLDP HSYDAVVWEP RTRLDFHAYA IFLMERIFDV QLPHYSPSDE
     KARMKLTLLH RELQALTEAM YTNLHAVLLG DATEAGSGWH EMGLLDFSYS FLLRAGYLTL
     YGIEALPRTH ESQAQDRVHS ADVFHTFRQL DRLLPKLARG SLSVGDKDHM CSVKSRLWKL
     LSPARLARRA HRSKWLESYL LHLEEMGVSE EMQARALVLQ LWATQGNMGP AAFWLLLFLL
     KNPEALAAVR GELESILWQA EQPVSQTTTL PQKVLDSTPV LDSVLSESLR LTAAPFITRE
     VVVDLAMPMA DGREFNLRRG DRLLLFPFLS PQRDPEIYTD PEVFKYNRFL NPDGSEKKDF
     YKDGKRLKNY NMPWGAGHNH CLGRSYAVNS IKQFVFLVLV HLDLELINAD VEIPEFDLSR
     YGFGLMQPEH DVPVRYRIRP
//
